GlassScriptPhysician profile
Thomas S Ellis
NPI 1629004445
$3,685.87
in general payments reported to CMS, 2019-2025
21 companies · $572 in 2025
The $572 reported for 2025 was less than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,807 · 2020: $111 · 2021: $283 · 2022: $340 · 2023: $215 · 2024: $358 · 2025: $572.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,144.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Globus Medical, INC. | $2,201.44 | 2019-2025 | Excelsius Gps, Rise, Modulus |
| Providence Medical Technology, INC. | $489.37 | 2022-2024 | |
| Medtronic, INC. | $108.27 | 2022 | |
| Nico Corporation | $92.40 | 2024 | |
| Arbor Pharmaceuticals, INC. | $89.12 | 2020-2021 | |
| Integra Lifesciences Corporation | $87.29 | 2019 | |
| Portola Pharmaceuticals, LLC | $83.64 | 2019 | |
| Stryker Corporation | $81.68 | 2021 | |
| Intrinsic Therapeutics | $80.98 | 2021 | |
| Baxter Healthcare | $74.64 | 2023-2024 | Floseal |
| Vertex Pharmaceuticals Incorporated | $53.95 | 2025 | |
| Pfizer INC. | $52.22 | 2021 | |
| Nevro Corp. | $32.54 | 2019-2020 | |
| Orthofix Medical, INC. | $31.33 | 2019-2022 | |
| Theragen, INC. | $27.18 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kci USA, INC. | $24.94 | 2020 | |
| Ethicon US, LLC | $23.56 | 2020 | |
| Medexus Pharma, INC. | $19.22 | 2023 | Gleolan |
| Arteriocyte Medical Systems, INC. | $16.10 | 2022 | |
| Omniscient Neurotechnology America LTD | $16.00 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$200,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Ellis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.